MANAGEMENT
Mrs. King is co-founder and CEO of GlycoMimetics, Inc. (GMI). Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis. After the sale to Novartis, she was named CEO and ran the company as a wholly-owned subsidiary of Novartis. Mrs. King also worked previously at ALZA Corporation in Palo Alto, CA and at Bain & Company in Boston. Mrs. King is the past Chair of the Board as well as past of the Chair Emerging Companies Governing Board of the Biotechnology Innovation Organization (“BIO”); she continues to serve on BIO’s executive committee. She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. Mrs. King now serves on the boards of Novavax, Inc. and the University of Maryland BioPark. She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School.
Dr. Magnani is co-founder and CSO of GlycoMimetics, Inc (GMI). Prior to co-founding GMI, Dr. Magnani founded and led a predecessor company, GlycoTech Corporation, as its President and CEO. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health (NIH). He remained at the NIH for 10 years, finally serving as a tenured research chemist. Dr. Magnani is an expert in glycobiology, having discovered and characterized many carbohydrate tumor antigens, such as the FDA-approved cancer diagnostic, CA19-9. He also developed fundamental technology for the identification of functional carbohydrate epitopes. Dr. Magnani is the discoverer of Sialyl Lea and its functions. He was the first to identify the binding domain to the selectins common to both Sialyl Lea and Sialyl Lex and used this information to develop potent selectin antagonists as drug candidates now in clinical trials. He is the recipient of the 2015 President’s Innovation Award from the Society of Glycobiology, has authored over 100 scientific publications and is an inventor on more than 90 issued patents.
Dr. Thackray joined GlycoMimetics in 2006. She has extensive leadership experience in design and execution of development programs for rare diseases, Orphan and Fast Track products. At GlycoMimetics, she oversees development of the company’s investigational products. Dr. Thackray is board-certified and an assistant clinical professor of pediatrics at the George Washington University School of Medicine. Previously, she was vice president of clinical product development at Biosynexus, Inc. She served as pediatric chief resident at Children’s National Medical Center, as a medical genetics fellow at the National Human Genome Research Institute of the National Institutes of Health, as a member of the Institutional Review Board of the National Center for Healthcare Statistics, and is a fellow of the American Academy of Pediatrics. She now serves on the ICH E11A Expert Working Group for the development of a harmonized guideline for pediatric extrapolation in drug development. Dr. Thackray received her B.S. from Stanford University and her M.D. from George Washington University School of Medicine.
Mr. Hahn has more than 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as executive director of finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly-traded specialty pharmaceutical company. Prior to Advancis, he was a senior accountant with Bering Truck Corporation. During the last 10 years, Mr. Hahn has worked with life science companies from early stages through product launch. He has been involved in multiple initial public offerings and has broad experience in developing strategic plans, creating business models, establishing accounting and auditing systems and ensuring Sarbanes-Oxley compliance. Currently, Mr. Hahn serves as co-chairman of the BIO Finance and Tax Committee, as a co-chairman of the Steering Committee of the Washington, DC chapter of the Association for Bio Financial Officers (ABFO), and also serves on the Securities and Exchange Commissions’ Advisory Committee on Small and Emerging Companies. He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.
Mr. Girard has extensive partnering experience, including the completion of collaborations, licenses, acquisitions and spinouts by and between leading pharmaceutical and biotech companies. As the GlycoMimetics Senior Vice President, Strategy and Corporate Development, he is responsible for corporate strategy, pursuing partnering and licensing opportunities in support of the GlycoMimetics pipeline and for managing the company's corporate and institutional alliances. Prior to joining GlycoMimetics, Mr. Girard held the positions of vice president for technical assessment and senior director for business development at Shire Pharmaceuticals. He has more than 20 years of business development, research and development and project management experience in life sciences for companies including Strakan Life Sciences, Pro-Virus, Inc. and Otsuka Pharmaceuticals. Mr. Girard holds an M.B.A. from St. Joseph's University Haub School of Business and a B.A. from Lehigh University.
Mr. Dinneen-Long has 15 years of in-house experience at several public pharmaceutical and biotechnology companies, with expertise in licensing and M&A transactions, corporate governance, securities regulations and SEC reporting and corporate finance. Prior to joining the company, Mr. Dinneen-Long served as Senior Counsel at AstraZeneca/MedImmune, where he supported strategic initiatives, pipeline programs and sophisticated transactions with values up to $2 billion. As Associate General Counsel at Emergent BioSolutions, Inc., he advised on complex corporate transactions, supported the company’s SEC reporting and provided legal advice to all functional areas of the business. He was also the Assistant General Counsel at Guilford Pharmaceuticals, managing all day-to-day legal operations, including providing legal support for multi-site Phase III clinical trials. Before joining the biotechnology field, Mr. Dinneen-Long spent eight years as an associate at law firms in Chicago, Kansas City and Washington, D.C. He earned his J.D. with honors from the Chicago-Kent College of Law and a Bachelor of Business Administration degree from the University of Wisconsin-Madison.
Dr. Feldman is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone marrow disorders. Before joining GlycoMimetics in 2019, he most recently served as Chief Medical Officer at Amphivena, focusing on breakthrough blood cancer treatments, and oversaw the myeloid leukemia antibody-drug conjugate (ADC) program at Seattle Genetics, Inc. He has led or participated in the conduct of numerous clinical trials, several leading to U.S. FDA approval. Dr. Feldman’s extensive academic career includes a recent position as Professor of Medicine and Director of the Hematological Malignancies Service at Weill-Cornell/New York Presbyterian Hospital, as well as faculty positions at New York Medical College and the University of Texas, MD Anderson Cancer Center. Dr. Feldman has authored over 150 scientific articles and is a former Editor-in Chief of the journal Leukemia Research. He earned his medical degree at New York Medical College and holds a B.A. from Tulane University.
Mr. Flanner has more than 20 years of experience in the development of biopharmaceutical products in emerging pharmaceutical companies. He joined GlycoMimetics in 2007, bringing knowledge and experience in chemistry, manufacturing and controls (CMC) and biopharmaceutics. At GlycoMimetics, he oversees the scale-up and optimization of manufacturing processes for production of clinical supplies. He also manages the non-clinical toxicology and pharmacokinetics programs for the company. Prior to joining GlycoMimetics, Mr. Flanner was senior director of pharmaceutical research at MiddleBrook Pharmaceuticals, and director of drug delivery sciences at Shire Laboratories. He holds over 20 formulation patents and co-developed the in vitro dissolution profile comparison factors, f1 and f2, cited in multiple regulatory guidances. He received a B.S. in Chemical Engineering from the University of South Carolina, and an M.S. in Chemical Engineering from Johns Hopkins University.
Dr. Fogler is the Vice President, Preclinical Studies in the Research Department of GlycoMimetics. He received his Ph.D. in Experimental Pathology form the University of Maryland at Baltimore under the guidance of Dr. Isaiah J. Fidler. He was awarded a National Research Council Research Associate award in 1985 to further study therapeutic approaches in what is now referred to as the tumor microenvironment. Dr. Fogler has more than 20 years of experience in biotechnology, designing and administering scientific/preclinical development programs in oncology and non-oncology. His expertise has included the development of small molecules, recombinant proteins and DNA-based therapeutics and he has authored 85+ publications.
Ms. Irish has served as Vice President, Accounting since January 2019 and previously held the positions of Senior Director, Accounting and Reporting, and Director, Accounting and Reporting, since joining GlycoMimetics in April 2014. Ms. Irish has more than 25 years in finance and accounting, with a significant portion of that time working for both private and public life science companies including Vanda Pharmaceuticals, Inc., Zyngenia Inc, Avalon Pharmaceuticals and The Institute for Genomic Research (TIGR). Ms. Irish is a Certified Public Accountant in the State of Maryland and holds a B.S. degree in Business Administration from the University of Maryland, College Park. She is a member of both the Maryland Association of Certified Public Accountants (MACPA) and the American Institute of CPAs (AICPA).
Mrs. Mongold joined GlycoMimetics in 2018 with more than 20 years of experience in Human Resources Management within the biopharmaceutical industry. At GlycoMimetics, she leads human resource functions, including leadership development, organizational design, staffing and recruitment, and compensation strategies. Prior to joining the company, she had a consulting practice that focused on early-stage through maturing companies with clients in the U.S., Europe, and Australia. Mrs. Mongold was the head of Human Resources for GenVec, Inc. and was the Senior Director, Human Resources at EntreMed, Inc. for five years. She also led the Human Resources function for Genetic Therapy, Inc. for five years. Mrs. Mongold earned a B.A. in Psychology and Sociology from American University and received her M.A. in Human Resource Management from George Washington University. She is certified in Myers–Briggs Type Indicator and Frontline Leadership. She is an active member of the Society for Human Resources Management.
Dr. Peterson has more than 25 years of experience in drug discovery. Having joined GlycoMimetics in 2012, he manages the company's internal and external discovery chemistry efforts and provides strategic guidance on drug candidate optimization. Prior to joining GlycoMimetics, Dr. Peterson was Principal Scientist at H Lundbeck A/S where he served as Project Leader for several CNS related programs. Prior to that, he was a Distinguished Research Fellow at Neurogen Corporation where he managed the Hits to Lead group. Dr. Peterson received a Ph.D. in Chemistry from Yale University where his research focused on oligosaccharide synthesis – including the E-selectin ligand sialyl Lewisx